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Tandem mass spectrometry (MS/MS) has become a leading
technology used in clinical chemistry and has shown to be
particularly sensitive and specific when used in newborn
screening (NBS) tests. The success of tandem mass spectrometry
is due to important advances in hardware, software and clinical
applications during the last 25 years. MS/MS permits a very
rapid measurement of many metabolites in different biological
specimens by using filter paper spots or directly on biological
fluids. Its use in NBS give us the chance to identify possible
treatable metabolic disorders even when asymptomatic and the
benefits gained by this type of screening is now recognized
worldwide. Today the use of MS/MS for second-tier tests and
confirmatory testing is promising especially in the early detec-
tion of new disorders such as some lysosomal storage disorders,
ADA and PNP SCIDs, X-adrenoleucodistrophy (X-ALD),
Wilson disease, guanidinoacetate methyltransferase deficiency
(GAMT), and Duchenne muscular dystrophy. The new challenge
for the future will be reducing the false positive rate by using
second-tier tests, avoiding false negative results by using new
specific biomarkers and introducing new treatable disorders in
NBS programs. # 2015 Wiley Periodicals, Inc. Rapid
Commun. Mass Spectrom. 9999: XX–XX, 2015.
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I. INTRODUCTION
The use of mass spectrometry (MS) in clinical laboratories is
very much increased on the outset of the 21st century. This
development is obviously due to great advances in MS
hardware, software and research in the last 25 years.
MS permits a very rapid measurement of many metabolites
in different biological specimens using filter paper spots or
directly in biological fluids. Because of its high sensitivity and
specificity, this technique can be used for qualitative and
quantitative analysis of many analytes, such as amino acids and
acylcarnitines, organic acids, homocysteine, orotic acid, purines
and pyrimidines, steroids, and vitamin D to name a few, with
appropriate internal standards.
Newborn screening (NBS) is definitely one of the most
successful applications of MS in clinical chemistry in the recent
years. The measurement of amino acids and acylcarnitines
enables the identification of many inborn errors of metabolism
(IEM) few days after birth. If they are not diagnosed and early
treated, most of them might cause mental and/or growth
retardation, severe permanent sequelae and in some case death.
The history of NBS as population-based test started in
1960s when Robert Guthrie developed a simple and cheap
bacterial inhibition assay on filter paper spot able to identify the
phenylketonuria (PKU), the most frequent aminoacidopathia
(Guthrie & Susi, 1963). The following development of electro-
spray tandem mass spectrometry (ESI-MS/MS) in more recent
years (1990s) has permitted the introduction of this new
technology in clinical chemistry laboratories, in particular for
newborn screening purposes (Rashed et al., 1995).
Originally, fast atom bombardment (FAB) and thermospray
(Yergey et al., 1984; Millington et al., 1991) were used to
measure carnitine and acylcarnitines in plasma samples for the
detection of fatty acid disorders.
Later on, advancements in MS/MS and research demon-
strated that the analysis of acylcarnitines could be used to
identify fatty acid oxidation defects in a neonatal population
from dried blood spots. In fact, carnitine and its derivatives
were ideal molecules for a MS/MS screening technique since
they all presented a common product ion (85m/z) containing a
quaternary ammonium function. These structural characteristics
enabled the detection of a panel of saturated, unsaturated, and
hydroxylate acylcarnitines with high specificity and sensitivity.
More or less in the same years, FAB-MS/MS was also used
for the first attempt to measure phenylalanine and tyrosine for
PKU diagnosis (Chace et al., 1993). The procedure required
esterification (as butyl esters) to enhance surface ionization in a
glycerol matrix. The butylation “quenched” the negative charge
on the acid moiety of phenylalanine increasing ionization
efficiency and sensitivity.
During the first tests other amino acids were identified
deducing a common neutral product, the butylformate, present-
ing with a mass of 102Da. Since then, the common neutral loss
of 102Da is the basis for the MS/MS assay of several key
butilated amino acids in newborn screening.
While butyl esterification assays are now routine, in the last
10 years new methods were developed able to detect amino
acids and acylcarnitines as their native free acids (underivatized)
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in an attempt to simplify analytical operations and to minimize
the use of butanol in chloridic acid.
Derivatized and underivatized methods with some modifi-
cations with respect to the original version are now worldwide
used in clinical chemistry labs and we should consider that
many millions of newborns are today screened for a variable
number of diseases by meaning of that test.
But the high number of disorders covered in expanded
newborn screening corresponded also to the increase in the
recall rate (Tarini, Christakis, & Welch, 2006). False-positive
screening results may cause unnecessary parental stress and
influence the child–parent relationship (Gurian et al., 2006). On
the other hand, a number of false-negative cases, have been
reported by several newborn screening laboratories (Wilcken
et al., 2003; Frazier et al., 2006).
In fact, some important metabolites in expanded newborn
screening programs, markers of diseases, have proven to have
poor specificity, causing a critical impact on the population due
to the high number of recalls. The best way to decrease the recall
rate, due to false positive results in the primary screening test, is
represented by the introduction of the second-tier test, per-
formed on the same NBS specimen with no necessity to
additionally contact patient’ family. Second-tier test result over-
rules the primary result.
Since for some metabolites there is an overlap between
controls and patients ranges, second-tier test proved its superior-
ity in discriminating the two populations thanks to the high
specificity.
The choice of reference values for NBS test should be a
good compromise between sensitivity and specificity; a good
sensitivity could result in a high false positive rate while having
high specificity could cause false negative results. Adjusting
cutoff values for each metabolite should consider the availability
of a second-tier test; if it is available, primary test cut-off should
be reduced to capture presumptive positive cases (Chace &
Hannon, 2010).
Near the proliferation of new second-tier tests, advances in
computerization, automation, and sensitivity of analytical
instruments have resulted in the expansion of potential new NBS
tests in recent years. Furthermore, improvements in treatments,
such as gene therapy, bone marrow transplantation, enzyme
replacement, and chaperone therapy, have raised the status of
some disorders as candidates for NBS. The availability of a
effective treatment is the worldwide approved criterion to
include a disorder in a newborn screening panel.
In the last years NBS tests have been proposed for
lysosomal storage disorders, Duchenne muscular dystrophy,
GAMT, peroxisomal disorders, SCIDs, andWilson’s disease.
While pilot projects have demonstrated the potential of
these tests, it remains to be discussed how effectively they can
be applied in most NBS centers and how effective the newer
treatments are. Each new test appends an additional complexity
to the NBS program and some of the therapies are costly and
long-term, often lifelong.
II. SECOND-TIER TESTS IN EXPANDED NEWBORN
SCREENING
Expanded NBS by tandem mass spectrometry is normally
performed by a flow injection analysis; since it does not require
prior chromatographic separation, potential interference is
possible. Second-tier testing is performed on newborns with
abnormal screening result. It is considered a second level test
performed on the original blood spot, in order to find a target
analyte under optimum operating conditions. The introduction
of second-tier testing, in newborn screening programs, has
allowed the reduction of the number of false positives that were
not only the cause of unnecessary parental stress but also
resulted in the increase of laboratory analyses and personnel
costs due to repeat tests. However, second-tier tests cannot be
used as primary screening tests because of the low-throughput
assay and laboratory costs (Chace & Hannon, 2010).
There are two categories of second-tier tests: a test looking
for the same analyte identified in NBS analyses or a test looking
for additional diagnostic markers not detectable among NBS
analytes (Fig. 1).
In the first one, second-tier tests will obtain a more high
specificity than the NBS method, so a potential false-positive
interference from NBS process may be excluded. Some authors
consider these methods part of primary screening instead of a
real second-tier test (Chace & Hannon, 2010). However, these
tests meet fully the definition of second-tier tests, as they
distinguish true from false positives and improve the positive
predictive value of primary NBS results. Using this strategy,
several two-tier tests have been developed such as succinylace-
tone (SUAC), a specific marker for Tyrosinemia I (OMIM
276700), recently included in the NBS panel (la Marca et al.,
2008; Turgeon et al., 2008). Although, in our experience, false
positive rates for SUAC are very low (la Marca et al., 2011), a
sample contamination cannot be excluded. A newborn falsely
suspected for Tyr I causes a high cost of hospitalization, without
considering the parental stress involved. To overcome this
problem, the specificity of some important diagnostic markers
of diseases which require immediate hospitalization should have
the highest possible specificity.
In the other case, second-tier tests identify diagnostic
metabolites, not available by routine NBS, by strongly support-
ing the presence of disorder.
The identification of free methylmalonic or propionic acid
on DBS, after an abnormal propionylcarnitine (C3) result, has
been revealed one of the most effective second-tier tests. A high
C3 (also >10mmol/L) is not a real diagnostic marker contrari-
wise the presence of free organic acids has a pathognostic
importance. By using this second-tier test, the recall rate for C3
has been drastically reduced as previously reported (la Marca
et al., 2007).
In the other cases, separation of isomers by second-tier
testing can resolve multiple diagnostic possibilities. High levels
of the branched-chain amino acids, revealed on NBS process,
could be due to total parenteral nutrition or to maple syrup urine
disease (MSUD, OMIM 615135). Alloisoleucine (allo-Ile) is the
pathognomonic marker of MSUD, but it cannot be differentiated
in flow injection from isobaric amino acids (leucine, isoleucine,
and hydroxyproline; la Marca et al., 2005). Hydroxyprolinemia
(OMIM 23700) is a benign condition for which recall is not
recommended. A second-tier test has been shown to be able to
identify each isobaric compound, permitting unequivocal inter-
pretation of NBS results (Oglesbee et al., 2008).
Second tier steroid profiling by MS/MS can be also
performed for congenital adrenal hyperplasia (CAH, OMIM
201910), for which NBS programs are fluorescence based. The
false positive rate of CAH screening is much higher than other
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screens and by using MS/MS in the second-tier tests, the
specificity of NBS results improve (Schwarz et al., 2009),
although not completely eliminating false-positive results but
this benefit is opposed by the increased risk of false negatives as
reported by Sarafoglou et al. (2012). These authors suggested
that molecular testing as a second-tier test could have a major
efficacy but cost effectiveness has not yet been evaluated.
However, MS/MS is a powerful technique that has very
high analytical sensitivity and selectivity and so its poor
effectiveness as second-tier test for CAH screening could be due
to the lack of a consistent algorithm system, which determines
the positive or negative results.
Many countries perform newborn screening to detect
classic galactosemia (GALT deficiency, OMIM 230400) due to
a deficiency of the galactose-1-phosphate uridyl transferase
(GALT) enzyme. The first screening test can be performed either
by fluorometric assay (Fujimoto et al., 2000) or by MS/MS
(Jensen et al., 2001). In particular some false positive results by
fluorimetric assay have been reported in DBS exposed to high
temperature and humidity (Fujimoto et al., 2000; Ohlsson et al.,
2012). In recent years, some second-tier tests able to reduce
false positive rate have been developed, including multiplex
enzyme testing by UPLC-MS/MS (Ko et al., 2011).
The combination of first and second-tier testings for many
metabolic disorders can be considered the best working practice
to achieve the most benefit out of newborn screening programs.
A list of MS-based second-tier tests is reported in Table 1.
III. SEVERE COMBINED IMMUNODEFICIENCY
(SCID)
Severe combined immunodeficiency (SCID, OMIM 615615) is
currently a genetically and clinically heterogeneous group of
disorders belonging to primary immunodeficiency disorders
(PIDDs) that result from thymic dysplasia and arrest in T
lymphocyte maturation. There is also variable expression of B
and natural killer (NK) cells, and patients are categorized into
either SCID with absence of T lymphocytes but presence of B
lymphocytes (T-Bþ SCID) or SCID with absence of both T and
B lymphocytes (T-B- SCID) (Somech & Etzioni, 2014). These
diseases can be inherited either in an X-linked or an autosomal
recessive manner.
Infants with SCID might be difficult to diagnose in the
neonatal period because in most cases they are initially
asymptomatic, (Geha et al., 2007; Slatter & Gennery, 2008), but
a prompt identification and treatment may lead to less severe
clinical symptoms and avoid fatal consequences.
Valid therapeutic options are represented from bone
marrow transplantation (Slatter & Gennery, 2008; Gaspar et al.,
2014) and enzyme replacement therapy. Recently, gene therapy
has shown to be a highly effective treatment for infants with
Adenosine Deaminase deficiency (ADA-SCID, OMIM 102700)
FIGURE 1. A: MS/MS analysis of Newborn Screening DBS from a patient affected by tyrosinemia type I. B:
Extract ion chromatogram of m/z 155.1> 137.1 and 159.1> 141.1 for Suac and [13C4]-Suac during second-tier
test.C: Partial acylcarnitine profile without derivatization in a newborn affected by methylmalonic aciduria Cbl C.
D: Extract ion chromatogram of m/z 117> 73 and 120> 76 for MMA and [2H3]-MMA. Retection time was
approximately 1.7min.
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and X-linked SCID (X-SCID, OMIM 300400; Aiuti et al., 2009;
Hacein-Bey-Abina et al., 2010; Gaspar et al., 2011a,b).
SCID shows all the characteristics required by neonatal
screening programs and they were first introduced in 2008 in
Wisconsin by T-cell receptor excision circles (TREC) assay and
Massachusetts joined in 2009 and then several other states
(Chase, Verbsky, & Routes, 2011).
TREC are DNA biomarkers of normal T cell development
(Somech & Etzioni, 2014) and their quantification by real-time
PCR on DBS currently represents the only test available to
screen for SCID in routine NBS programs (Gaspar et al., 2014).
This test is shown to be a cost-effective test for SCID, due
to the low cost of the TREC assay and to the extremely high
costs associated with delayed identification and treatment (Chan
et al., 2011).
The introduction of NBS for SCID using the TREC assay
showed important advantages in early diagnosis and treatment
of patients (Routes et al., 2009; Hale et al., 2010; Accetta et al.,
2011); each state developed its own screening algorithm
resulting in a great variability between areas (Chase, Verbsky, &
Routes, 2011) .
High false-positive TREC assay rates are generated from
infants born prematurely (Routes et al., 2009).
ADA-SCID represents the second most common form of
SCID (Buckley, 2004; Booth et al., 2007; Gaspar et al., 2009);
adenosine deaminase dysfunction causes accumulation of me-
tabolites, including 2-deoxyadenosine (DAdo) and deoxyadeno-
sine triphosphate, which inhibit the activity of ribonucleotide
reductase and ultimately DNA synthesis. The incidence of ADA
deficiency is estimated to be between one in 375,000 and one in
660,000 live births (Sauer & Aiuti, 2009) but it might be
underestimated because of early death from infective diseases or
disorders caused by toxic metabolites (Azzari, la Marca, &
Resti, 2011).
Different ADA deficiency phenotypes have been described
depending on the clinical onset and on the severity of the
disease: the most severe form, presenting in infancy and usually
resulting in early death, is “early onset” ADA-SCID; “delayed”
onset concerning about 10–15% of patients; “later” onset
characterized by less severe infections and “partial” ADA
deficiency occurs in a subset of immunocompetent individuals
(Arredondo-Vega et al., 1994). The incidence of late-onset ADA
deficiency is also underestimated, even more than that of early
onset ADA-SCID (Arredondo-Vega et al., 1998).
SCID NBS by TREC assay can identify newborns with
early-onset ADA-SCID but it has been shown to be unable to
identify newborns with delayed or late-onset ADA-SCID (la
Marca et al., 2013).
In 2010, our group set up a MS/MS based method to detect
ADA-SCID biomarkers, 2-deoxyadenosine and adenosine
(Ado), on DBS from newborn screening cards. Results demon-
strated that patients with ADA-SCID can be easily diagnosed at
birth by using the existing underivatized acylcarnitine and
aminoacid method (Azzari, la Marca, & Resti, 2011; Fig. 2). A
two step extraction derivatized method is also possible (la
Marca, 2014a). The method seemed to be promising and a pilot
project for a population-based neonatal screening in Tuscany
started in September 2010. The method resulted applicable also
to premature infants whose mean levels of metabolites do not
differ from those found in full-term babies. In 2011, the first
diagnosis of ADA-SCID was made through expanded newborn
screening including ADA metabolites quantification. The pa-
tient was confirmed by molecular analysis as a late onset
phenotype. Normal TREC were detected on neonatal DBS (la
Marca et al., 2014b).
At the beginning of 2013, Purine nucleoside phosphorylase
deficiency (PNP, OMIM 613179) was also included in the MS/
MS newborn screening panel of the Tuscany region (la Marca
et al., 2014b).
PNP deficiency is a rare form of SCID (Markert, 1991; Al-
Saud et al., 2009; Somech et al., 2013); the enzyme catalyses the
phosphorolysis of guanosine, deoxyguanosine, inosine, and
TABLE 1. Second tier tests performed by mass spectrometry
NBS MARKER NBS ASSAY MARKER II-TIER TEST REFERENCES
Propionylcarnitne (C3) TMS free methylmalonic and propionic acids on blood la Marca et al., 2007
Succinylacetone TMS Succinylacetone la Marca et al., 2011
Methionine ( ) for homocystinuria
Methionine ( ) for MTHFR TMS Homocysteine Turgeon et al., 2010
17-Hydroxyprogesterone immunoassay 17-hydroxyprogesterone, cortisol, androstenedione Peter et al., 2008
Branched-chain amino acids TMS alloisoleucine, leucine, isoleucine, valine, OH-proline Oglesbee et al., 2008
Isovalerylcarnitine (C5) TMS
free isovaleric acid or 
isovalerylcarnitine separed from 2-
methylbutyrylcarnitine and pivalic acid
Forni et al., 2010
Isobutyrylcarnitine (C4) TMS
free ethylmalonic acid or 
isobutyrylcarnitine separed from 
butyrylcarnitne
Forni et al., 2010
Creatine and Guanidinoacetate TMS creatine and guanidinoacetate Pasquali et al., 2014
Total galactose and/or GALT 
activity immunoassay
Galactose-1-phosphate, UDP-
galactose, and UDP-galactose Ko et al., 2011 
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deoxyinosine to their respective purine bases and pentose-1-
phosphates (Hershfield &Mitchell, 2001). Lack of PNP function
determines an intracellular accumulation of deoxyguanosine
triphosphate derived from deoxyguanosine, toxic to lymphoid
cells and resulting in various neurologic abnormalities (Hersh-
field, 2004; Myers et al., 2004; Al-Saud et al., 2009). As for
ADA-SCID, incidence and prevalence remain unknown because
of misdiagnosis and insufficient available laboratory testing.
MS/MS can easily identify abnormal metabolites in DBS
for PNP patients at birth as shown by retrospective studies on
DBS samples from patients with genetically confirmed PNP
deficiency.
When ADA and PNP SCID were added to the expanded
newborn screening panel, a cost-effectiveness evaluation was
performed. SCID metabolites inclusion was carried out without
any additional operator intervention, sample preparation stages
and any additional instrumentation beside that necessary for
routine neonatal screening. Therefore, the cost was calculated
for reagents only and rounded up to a few euro cents per
newborn.
IV. LYSOSOMAL STORAGE DISORDERS
The lysosomal storage disorders (LSDs) are rare inherited
diseases caused by a deficiency of one or more specific
lysosomal enzymes, activator protein or membrane protein,
resulting in deficient enzymatic activity. The defect causes the
progressive accumulation of the substrate interfering with
normal cellular activity and possibly resulting in cellular death.
LSDs represent a group of more than 50 different diseases
(Filocamo & Morrone, 2011; la Marca, 2014c) and have a
combined incidence of about 1 in 1,500–7,000 live births (Stone
& Sidransky, 1999; Fletcher, 2006).
Most affected newborn seems to be healthy at birth but they
can develop a wide range of clinical manifestations within the
first few years of life. If left undetected and untreated, these
diseases can lead to different clinical symptoms depending on
the specific disorder. An early treatment could prevent these
serious problems.
Thanks to the new effective therapeutic options available
for some LSDs (Escolar et al., 2005; Urbanelli et al., 2011;
Parenti et al., 2013; Ortolano et al., 2014) and to the
development of new analytical methods to test enzyme activity
on DBS specimens, these disorders have become strong
candidates for inclusion in future mandatory screening panels.
Although in 2006 the American College of Medical
Genetics (ACMG) Newborn Screening Expert Group declared
LSDs as not appropriate for newborn screening because they did
not meet the current evaluation criteria, more recently the
Discretionary Advisory Committee on Heritable Disorders in
Newborns and Children (DACHDNC) recommended to include
Pompe disease to the Recommended Universal Screening Panel
(RUSP) for all north American newborns (http://www.hrsa.gov/
advisorycommittees/mchbadvisory/heritabledisorders/recom-
mendations/correspondence/uniformpanel060313.pdf).
There are net evidences that presymptomatic diagnosis and
early treatment for some LSDs can favorably modify the natural
progression of the disease (Chien et al., 2009; Muenzer, 2014).
An additional argument for inclusion of LSDs in NBS
programs is the relative prevalence of these conditions. The
incidence of LSDs is not known but, surprisingly, pilot NBS
programs for Fabry disease revealed an incidence of 1 in3,100
FIGURE 2. Newborn screening analysis by flow injection from a newborn confirmed to have ADA-SCID. (Top),
unbutylated acylcarnitine profile acquired through a precursor ion scan of 85Da. (Middle), amino acid profile
obtained by neutral loss scan of 48Da. (Bottom), simultaneous MRM acquisitions of m/z 268.2> 136.1 (Ado),
169.2> 136.1 ([13C1]-ado), 252.2> 136.1 (DAdo), 257.2> 136.1 ([
13C5]-DAdo).
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in Italy (Spada et al., 2006) and 1 in 1,250 in Taiwan (Hwu
et al., 2009) in male newborns.
Some countries already include some LSDs into their
newborn screening panels, and local or pilot programs have
been launched in others (Chien et al., 2008; Paciotti et al., 2012;
Wittmann et al., 2012; Inoue et al., 2013; Liao et al., 2014).
The state of New York was the first state to perform
population screening for the lysosomal disorder Krabbe disease
starting in 2006 (Duffner et al., 2009).
In the Tuscany region of Italy, a prospective pilot project
screening program for Pompe, Fabry, and Mucopolysaccharido-
sis type I has started in November 2014.
Going to technical procedures, the pioneering work of
Chamoles et al. (2004) first established the possibility of assay
lysosomal enzyme activity on DBS using fluorescence because
many of these enzymes are still active in re-hydrated DBS.
Fluorometric methods have been developed for many LSDs
such as Pompe disease, Gaucher disease, Fabry disease,
mucopolysaccharidosis (MPS), Hurler-like LSDs, Niemann-
Pick A/B disease, Tay–Sachs disease and Sandhoff disease
(Chamoles, Blanco & Gaggioli, 2001a,b; Chamoles et al.,
2002a,b). However, the incorporation of a chromophore or
fluorophore into the substrate caused false negative results and
had limitations of specificity and limited capacity for multi-
plexing. In the last year, new technology for simultaneous
screening of several enzyme activities related to lysosomal
storage disorders from DBS was developed replacing the old
methods enabling the assay of single enzyme activity (Li et al.,
2004; Zhang et al., 2008).
Li et al. firstly developed a direct multiplex assay of
lysosomal enzymes for Gaucher, Pompe, Krabbe, Fabry, and
Niemann-Pick A/B diseases in DBS by flow injection analysis
(FIA)-tandemmass spectrometry.
Later on, an expansion of simultaneously diagnosable
disorders by MS has been reported (Orsini et al., 2012; Spacil
et al., 2013).
Novel substrates, internal standards and assays have been
developed over the years for testing enzyme activity of Krabbe,
Pompe, Niemann-Pick A and B, Gaucher, Fabry, MPS-I, MPS-
II, MPS-III, MPS-IVA, and MPS-VI (Gelb et al., 2006; Wang
et al., 2007; Blanchard et al., 2008; Duffey et al., 2010a,b;
Khaliq et al., 2011; Wolfe et al., 2011; Chennamaneni et al.,
2014). Moreover in order to facilitate the introduction of LSD in
newborn screening panels, the Center for Disease Control and
Prevention distribute substrates and internal standards to inter-
ested newborn screening centres; QC programs are also
available (De Jesus et al., 2009).
The substrates used are structurally closer to the natural
substrates, the enzyme products are specific to each enzyme
reaction and are quantified against internal standards with
known concentrations for the measurements of enzyme activi-
ties (Li et al., 2004).
The multiplex assay developed by Li et al. was later refined
by (Zhang et al. (2008) to make it more suitable for newborn
screening laboratories. These methods required liquid or solid-
phase extraction and subsequent FIA-MS/MS analysis to deter-
mine the concentration of each reaction product based on the
intensity of internal standards.
la Marca et al. (2009) simplified Zhang’s assay eliminating
the liquid/liquid and solid-phase extraction steps by using an
online trapping-and-cleanup liquid chromatography/mass
spectrometry method. As an example a chromatogram from a
LC-MS/MS combined six enzyme assay on DBS of a Pompe
patient is reported in Figure 3.
Furthermore, the introduction of the separation of
analytes by liquid chromatography (LC) coupled to the
tandem mass spectrometer (LC-MS/MS) was crucial (la
Marca et al., 2009; Kasper et al., 2010; Spacil et al., 2011).
In fact it has been demonstrated that a too high declustering
potential value in the mass spectrometer could cause a in
source breakdown of the substrate with an undue appearance
of the product (la Marca et al., 2009). Chromatographic
separation allowed the distinction of the real enzymatic
product from the one derived by the source breakdown of
the substrate.
In the last years, new sample preparation methods reporting
on a combination of substrates and internal standards into a
single buffer, for a triplex assay (Duffey et al., 2010c; Scott
et al., 2013) or a multiplex assay have been reported (Spacil
et al., 2013).
Mechtler et al. (2012) have recently published on a short-
incubation mass spectrometry-based protocol.
Metachromatic leukodystrophy (MLD) is a disorder caused
by the deficiency of the enzyme arylsulfatase A (ASA) and
resulting in the accumulation of 3-O-sulfogalactosyl ceramides
(sulfatides) in tissues.
Recently, a noteworthy interest for newborn screening of
MLD has arisen due to the development of potential therapies
(Biffi et al., 2013).
However, application of direct assay of lysosomal enzyme
in DBS seems to be difficult for MLD because trace amounts of
ASA activity are sufficient to minimize disease severity
(Renaud, 2012) and pseudodeficiency in ASA is a relatively
frequent condition in the normal population (Emre et al., 2000;
Lugowska et al., 2000).
Barcenas et al. (2014) in 2014 proposed a UHPLC/MS/MS
method to quantify sulfatides in DBS and dried urine
spots (DUS) for newborn screening of metachromatic
leukodystrophy.
However, they show that analysis of sulfatides on DBS is
problematic because their levels appear to be increased in some
but not in all DBS patient samples, while there was a good
separation between MLD and non-MLD samples using DUS.
These results suggest that urine sample collection should be
required for a reliable newborn screening program for metachro-
matic leukodystrophy.
Talking about neonatal screening for LSDs, some ethical
considerations must be made.
Considerations should be made about the best strategy to
treat presymptomatic individuals with positive screening results,
the best way to inform parents of the potential outcomes of the
affected individual and risks for future pregnancies.
Furthermore, newborn screening could potentially identify
adult-onset variants or variants of uncertain significance and
some patients with these variants may never develop symptoms
or require therapy. It must be also considered that effective
therapies are available only for few LSDs.
In addition LSD newborn screening could identify, as
previously described for ASA, enzymatic pseudodeficiency, in
fact there are some individuals showing a reduced enzyme
activity but they remain clinically healthy (Filocamo &
Morrone, 2011).
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If a newborn screening panel would include Fabry disease,
a complication could be the potential false negative of a female
affected with Fabry disease. In fact, Fabry disease is an X-linked
disorder and random X-inactivation results in highly variable
activity of alpha galactosidase in female patients with Fabry
disease. A negative newborn screening for Fabry disease in
female should be interpreted with caution (Linthorst et al.,
2005).
V. GUANIDINOACETATE METHYLTRANSFERASE
DEFICIENCY
Guanidinoacetate methyltransferase (GAMT, OMIM 601240)
deficiency is a rare creatine synthesis disorder resulting in a
developmental delay and intellectual disability. It is character-
ized by a depletion cerebral creatine and an accumulation of
guanidinoacetate (GAA) in the brain and body fluids. Early
diagnosis and treatment with creatine, ornithine, and an
arginine-restricted diet reduces the risk of neurological compro-
mise (Gordon, 2010; El-Gharbawy et al., 2013). For this reason,
GAMT deficiency might be a good candidate for newborn
screening.
In the last years, some pilot projects have been started
for newborn screening of GAMT deficiency (Mercimek-
Mahmutoglu et al., 2012; Pasquali et al., 2014). GAA and
creatine measurements can be included in the expanded
newborn screening by using butyl esterification assays
(Carducci et al., 2001). However, a high number of false
positives is reported during newborn screening because of an
overlap between the maximum value of GAA in healthy
newborns and the lowest value in GAA patients. This problem
can be solved by a second-tier test which allows to achieve the
positive predictive value to 100% (Pasquali et al., 2014). A
reliable method for the detection of Arginine: Glycine Amidino-
transferase Deficiency (AGAT, OMIM 612718; low levels of
both GAA and creatine) is still not present, given the variability
of creatinine levels with the time of collection and the significant
overlap of low levels with the normal population.
The detection of GAMT in the neonatal period has been
demonstrated to improve the severe neurological outcome
encouraging, with a minimal additional cost, the inclusion of
GAMT deficiency within the routine newborn screening (El-
Gharbawy et al., 2013).
VI. X-LINKED ADRENOLEUKODYSTROPHY
X-linked adrenoleukodystrophy (X-ALD) is a genetic disorder
caused by mutations in ABCD1 gene on the X-chromosome
resulting in the failure of peroxisomal oxidation of very long
chain fatty acids (VLCFA; Ferrer, Aubourg, & Pujol, 2010;
Kemp, Berger, & Aubourg, 2012). X-ALD is estimated to affect
1 in every 17,000 newborns (Bezman and Moser, 1998);
however, the true prevalence can be known only from the
newborn screening data.
The disease primarily affects the nervous system and the
adrenal glands with onset of symptoms at variable ages (Moser,
Mahmood, & Raymond, 2007). Phenotypes include rapidly
progressive childhood, adolescent, and adult cerebral forms;
FIGURE 3. Lysosomal enzymatic screening on DBS from Pompe patient. Chromatograms of substrates,
products, and internal standards for six lysosomal enzymes. The peak area corresponding to the transition m/z
498.4> 398.3 for GAA product is equivalent to the area obtained from a blank sample (data not shown) resulting
in a positive test for Pompe disease.
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adrenomyeloneuropathy, which presents as slowly progressive
paraparesis in adults and Addison disease without neurological
manifestations.
X-ALD could be added to the list of disorders that could
benefit from newborn screening because new therapies have
been developed in the last years and they show encouraging
promise for clinical outcomes (Moser, Raymond, & Dubey,
2005). In particular, hematopoietic stem-cell transplantation is
the most effective treatment that is often recommended but is
beneficial only if the patient has not already reached a stage with
irreversible brain damage. Thus an early diagnosis is critical for
improving the outcome of these patients.
The biochemical marker of XALD is the accumulation of
saturated very long-chain fatty acids (VLCFA) in tissues and
body fluids particularly of hexacosanoic acid (C26:0).
In 2006, an LC-MS/MS method has been developed to
measure lyso-phosphatidylcholines (L-PC) C20:0, C22:0, C24:0
e C26:0 on dried blood spots, in which C26:0 and its ratios
appeared the potential diagnostic marker for X-ALD. However,
this method required a gradient analysis that had a chro-
matographic run time of 13min/sample making it inconvenient
for newborn screening (Hubbard et al., 2006). The method was
slightly modified in 2009 (Hubbard et al., 2009) reducing run
time analysis to 7min/sample.
Recently, other methods have been proposed to make
newborn screening feasible: in 2012, Sandlers et al. (2012)
reported on a modified method from Hubbard 2009 for quantita-
tion of L-PC 26:0 able to reduce both sample preparation and
analysis time and to perform simultaneous extraction of
acylcarnitines. In a prospective study, nearly 5,000 newborn
blood spot samples were analysed by this method, providing
evidence that it can be applied as a high throughput method for
X-ALD newborn screening (Theda et al., 2014). In order to
further improve the efficiency of newborn screening for X-ALD,
Haynes and De Jesus (2012) developed a valve-switching
system able to acquire acylcarnitines and amino acids in positive
ion mode and L-PC 26:0 in negative ion mode to eliminate an
interfering compound that could result in false positives.
An early diagnosis of X-ALD through newborn screening
offers to these patients the best chance for treatment, thus an
implementation of NBS programs could be desirable. Presently,
heterozygous females, who are frequently symptomatic, remain
an unresolved problem. Carrier females have a reduced L-PC
26:0 accumulation and that could lead to false negative in blood
investigations (Berger & G€artner, 2006).
Two peroxisomal storage disorders have been clinically
diagnosed as X-ALD and Zellwegger syndrome (OMIM
214100) from 2004 to 2010 in Tuscany. A retrospective analysis
of butylated acylcarnitines on their neonatal DBS has been
performed by extending precursor ion scan of 85m/z upto 600
Th (range was set from 200 to 600m/z) and by adding
acylcarnitine C23 as internal standard to quantify very long
chain acylcarnitines. Their profiles revealed abnormal concen-
tration of C16DC, C18DC, C24, and C26 acylcarnitines in the
Zellweger syndrome neonatal DBS, as reported by Rizzo et al.
(2003) and an increase of C24 and C26 (but not C16DC and C18
DC) acylcarnitines in X-ALD sample (Fig. 4). The ratio C26/
C22 was also informative. Normal cutoff ranges for C16DC,
C18DC, C22, C24, and C26 were than calculated on 20,000
NBS samples; no abnormal values of these markers were found
(unpublished data).
Given the current poor data further evaluation should be
done in order to develop a reliable, sensitive, and specific
screening test for X-ALD patients.
VII. WILSON DISEASE
Wilson disease (WD; OMIM# 27790) is an autosomal recessive
disorder caused by mutations in the gene encoding the copper
transporting ATPase, ATP7B, that transports citosolic copper
into the lumen of the trans-Golgi network for incorporation in
ceruloplasmin (CP).
The enzyme defect reduces the incorporation of copper into
ceruloplasmin causing copper accumulation mainly in the liver
and in the central nervous system (deWilde et al., 2008) and a
reduction in ceruloplasmin levels in the bloodstream.
WD incidence is reported to be about 1/30,000 live births
but in some populations it is much more common (Figus et al.,
1995; Zappu et al., 2008).
The pharmacological treatments are represented by copper
chelators to promote its excretion from the body, zinc salts to
reduce its absorption in the intestine and liver transpantation
(Schilsky, 2009; Loudianos et al., 2014)
Due to the severity of the disease and to the existence of an
effective therapy approach, an early diagnosis is fundamental.
Usually the diagnosis of WD is performed through the
measurement of copper in liver tissue followed by molecular
confirmation with genetic testing of ATP7B gene (Hahn, 2014).
However level of ceruloplasmin in infants and newborns are
considerably lower than in adults and this complicates a
newborn screening programs due to a high rate of false positive
rate.
A measurement of ceruloplasmin on DBS through ELISA
assay, even if it is able to distinguish WD patients from healthy
control individuals, is critical for a successful screening program
because of the variation due to ceruplasmin antibody binding
(Kroll et al., 2006).
An antibody-independent method using LC-MS/MS to
quantify ceruloplasmin on DBS was developed by deWilde
et al. (2008). However this new approach requires a time
consuming sample preparation step (8 hr) due to trypsin
digestion and long chromatographic run for the separation of
specific CP peptides (7.5min).
Therefore, nowadays, due to the absence of an effective and
efficient approach for NBS, Wilson disease is not included in
newborn screening programs (Matern, Oglesbee, & Tortorelli,
2013).
VIII. SICKLE CELL DISEASE
Sickle cell disease (SCD) is an inherited disorder caused by a
replacement of a glutamic acid to a valine at position six on the
b-globin chain (Stuart & Nagel, 2004) resulting in the structural
variant hemoglobin S (HbS). The mutation causes sickling of
hemoglobin rather than reduced amount of b globin which
causes b-thalassemia (Galanello & Origa, 2010).
In homozygous state, HbS (HbSS) is responsible for anemia
and tissue damage due to the occlusions of blood vessels caused
by the abnormal red cells (Odievre et al., 2011).
Heterozygous state associated with normal hemoglobin A
(HbAS) is phenotypically silent, while different disease pheno-
types occur in compound heterozygotes in which HbS variant is
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coinherited with another haemoglobin mutant (e.g., HbC, HbD
Punjab/Los Angeles, or HbE).
SCD is associated with high mortality in early childhood
and an early diagnosis by newborn screening could increase
patient survival. Nowadays treatments help reduce the severity
and frequency of complications of SCD; among them, some
drugs that reduce HbS polymerization or stimulate HbF synthe-
sis reactivation (Brugnara et al., 1996; Fathallah & Atweh,
2006; Migliaccio et al., 2008), such as hydroxyurea (Tang et al.,
2005), have proved to be effective. Furthermore other important
therapeutic options are represented by stem cell transplantation
and transfusion programs (Styles & Vichinsky, 1994; Khoury &
Abboud, 2011) and recently studies are focused on gene therapy
(Sadelain et al., 2008).
Newborn screening programs for hemoglobin disorders can
be performed on cord blood or on DBS by isoelectric focusing
(IEF) or cation exchange HPLC (ceHPLC) HPLC–UV; these
methods frequently produce results of difficult interpretation
and data must be confirmed by second line testing using DNA
sequencing or amino acid analysis by tandemmass spectrometry
(Old, 2003).
Tandemmass spectrometry has recently been considered an
alternative screening approach for the characterization of
hamoglobin variants; different methods are used including the
detection of the intact globin chains masses or analysis of tryptic
peptide fragments (Boemer et al., 2008). Edwards et al. (2014)
developed a method in which automated direct surface sampling
of the DBS is coupled to top–down MS of the intact globin
chains.
MS/MS for diagnosis of clinically significant Hb variants
could be easily transferred for use in neonatal hemoglobinopa-
thy screening due to the reasonable running cost, analytical
sensitivity, and specificity and speed of analysis.
IX. CONCLUDING REMARKS
The NBS program is a complex process that is dependent on a
multidisciplinary team which includes pediatricians, geneticists,
dieticians as well as biologists, chemists, and technicians with
expertise in mass spectrometry. The collaboration of all these
professionals has contributed to the success of NBS for over
20 years and consequently to the beneficial impacts on public
health care. Present trends in NBS are aimed at expanding
testing panels in order to cover a wide range of conditions.
Research including more testing in NBS and new therapeutic
strategies has made noteworthy steps forward in this field.
FIGURE 4. Partial precursor 85 full-scan analysis of acylcarnitines. The spectrum of X-ALD patient displayed
most prominent ion signals consistent with C26:0 and C24:0 compared to the same signals in a control. C23:0 was
added to the samples before extraction as an Internal Standard.
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However, the expansion of NBS raises some questions and
the discussion of which disorders should be added to a NBS
panel is still ongoing worldwide.
In any case, there are no doubts that the model of newborn
screening and MS in preventive medicine may be exemplary in
developing other clinical applications that go beyond metabolic
disorders. Although there will be many challenges to the further
expansion of MS in clinical chemistry, it is clear that this
technique will play a fundamental role in the future.
ABBREVIATIONS
ADA adenosine deaminase
Ado adenosine
AGAT arginine:glycine amidinotransferase
ASA arylsulfatase A
CAH congenital adrenal hyperplasia
CP ceruloplasmin
C3 propionylcarnitine
DAdo 2-deoxyadenosine
DBS dried blood spot
DUS dried urine spot
ESI-MS/MS electrospray tandem mass spectrometry
FAB fast atom bombardment NBS newborn screen-
ing
FIA flow injection analysis
GAA guanidinoacetate
GAMT guanidinoacetate methyltransferase
Hb hemoglobin
IEF isoelectric focusing
IEM inborn errors of metabolism
L-PC lyso-phosphatidylcholines
LSD lysosomal storage disorders
MLD metachromatic leukodystrophy
MPS mucopolysaccharidosis
MSUD maple syrup urine disease
NK natural killer
PKU phenylketonuria
PNP purine nucleoside phosphorylase
SCD sickle cell disease
SCID severe combined immunodeficiency
SUAC succinylacetone
TREC T-cell receptor excision circles
VLCFA very long chain fatty acids
X-ALD X-linked adrenoleukodystrophy
WD Wilson disease
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